Research Infrastructures

Infrastructure for Preclinical and early-Phase Clinical Development of Drugs, Therapeutics and Biomedical Devices (EATRIS-GR)

OPENSCREEN-GR

Infrastructure for Preclinical and early-Phase Clinical Development of Drugs, Therapeutics and Biomedical Devices (EATRIS-GR)

EATRIS-GR is a Distributed Research Infrastructure of Greek Institutions that aim to combine the collective effort of Greek universities and research institutes, with substantial input from pharmaceutical/biotech enterprises and coalition with members of the EATRIS-EU to promote Translational Drug Research. EATRIS-GR envisions to provide high-quality services to all potential users by transforming efficiently a series of basic discoveries made by academic or private/industrial researchers into innovative drug products for clinical applications. The goal of the infrastructure is to substantially contribute to the improvement of public health, human potential and economic growth.

The key-objectives of EATRIS-GR are:

• To integrate the operational capabilities of existing cutting-edge infrastructures necessary for "Preclinical and early-Phase Clinical Development of Drugs, Therapeutics and Biomedical Devices".
• To provide access and "high-end" services according to international quality standards to translational research efforts at the national level serving the needs of the public and private sectors.
• To evaluate and adopt for its Infrastructures the operation, management, and governance rules of EATRIS-EU best suited for Greece; and
• To integrate EATRIS-GR operationally into the EATRIS-EU network, thereby advancing Translational Research efforts at the European level.

EATRIS-GR is established to provide services focusing specifically on preclinical and early-phase clinical development of drugs, therapeutics and biomedical devices through synergies between state-of-the-art research hubs and innovative facilities. The multidisciplinary nature of EATRIS-GR is strongly complemented through collaborations with other RIs such as OPENSCREEN-GR BIOIMAGING, ELIXIR and BBMRI to support the entire drug discovery and development pipeline.

OPENSCREEN-GR integrates high-capacity screening platforms throughout Greece, which jointly used a rationally selected collection, comprising up to 60000 commercial and proprietary compounds collected from Greek chemists.  OPENSCREEN-GR offers to researchers from academic institutions, SME’s and industrial organizations open access to its shared resources. 

OPENSCREEN-GR will collaboratively develop novel molecular tool compounds with external use from various disciplines of the life sciences.

BRFAA’s role is to provide nationwide access to:

• the metabolic stability and pharmacokinetic studies of the bioactive compounds that stem from the program (Dr Constantin Tamvakopoulos, Tamvakopoulos Lab)
• the assessment of the activity and toxicity of lead compounds using zebra fish models (Dr Dimitris Beis, Beis Lab, www.zebrafish.gr)
• Computer-aided drug design and in silico studies (Dr Zoe Cournia, Cournia Lab, www.drugdesign.gr).

Through its participation in the OPENSCREEN-GR: BRFAA will be actively linked to the national research community and interconnected production units and will have a key role in national initiatives and future funding efforts in the area of ​​discovery of drugs. BRFAA will benefit from a significant enhancement in its existing infrastructures (new instrumentation and personnel).  Importantly, through its participation in OPENSCREEN-GR, BRFAA will benefit through the interconnection of OPENSCREEN-GR with the corresponding OPENSCREEN-EU ERIC 

H εργασία αυτή υλοποιήθηκε στο πλαίσιο της Πράξης «OPENSCREEN-GR» (MIS 5002691) που εντάσσεται στη Δράση «Ενίσχυση των Υποδομών Έρευνας και Καινοτομίας» και χρηματοδοτείται από το Επιχειρησιακό Πρόγραμμα «Ανταγωνιστικότητα, Επιχειρηματικότητα και Καινοτομία» στο πλαίσιο του ΕΣΠΑ 2014-2020, με τη συγχρηματοδότηση της Ελλάδας και της Ευρωπαϊκής Ένωσης (Ευρωπαϊκό Ταμείο Περιφερειακής Ανάπτυξης).